Utah Medical Products, Inc.
$69.49-$1.47 (-2.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $216.5M
- P/E
- 19.2x
- EV / EBITDA
- 9.1x
- Revenue
- $38.5M
- Net margin
- 29.3%
- ROCE
- 9.6%
Price chart
Technical chartScreen technicals →+29.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -7.4%
- 3M
- -2.7%
- 6M
- +8.3%
- 1Y
- +29.2%
- 5Y
- -39.9%
52-week range
Day change -$1.47 (-2.1%) from $71 to $69 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in UTMD, bought on each weekday since 2021.
News & filings
What Utah Medical Products filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthFree cash flow was 37.2% of revenue in fiscal 2025.
Concerns (1)
- Return on equity of 9.5%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Read moreShow less
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
- Sector
- Healthcare
- Shares outstanding
- 3.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $216.5M
- P/E
- 19.2x
- P/B
- 1.8x
- EV / EBITDA
- 9.1x
- EV / Sales
- 3.4x
- P/S
- 5.6x
- 52-week high
- $76.66
- 52-week low
- $53.80
Profitability
- Operating margin
- 29.6%
- Net margin
- 29.3%
- EBITDA margin
- 37.4%
- ROE
- 9.5%
- ROCE
- 9.6%
- ROIC
- 27.0%
- ROA
- 9.2%
- Asset turnover
- 0.31
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $38.5M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -5.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -9.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -18.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $14.3M
Solvency
- Current ratio
- 37.59
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 1.30
- Cash / Market cap
- 39.6%
Where the revenue went
Of every $100 of FY2025 revenue, $29 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $16.5M |
| Revenue | Gross profit | $22.0M |
| Gross profit | Research and development | $670.0k |
| Gross profit | Selling, general and administrative | $9.9M |
| Gross profit | Other operating expenses | $0.00 |
| Gross profit | Operating income | $11.4M |
| Operating income | Pretax income | $11.4M |
| Interest and other income | Pretax income | $2.7M |
| Pretax income | Tax and other | $2.8M |
| Pretax income | Net income | $11.3M |
Revenue and net profit
Revenue fell 5.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $52.3M | $16.5M |
| FY2023 | $50.2M | $16.6M |
| FY2024 | $40.9M | $13.9M |
| FY2025 | $38.5M | $11.3M |
Cash flows
FY2025: $14.7M from operations, $14.3M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $21.1M | $20.3M |
| FY2023 | $22.3M | $21.6M |
| FY2024 | $14.8M | $14.6M |
| FY2025 | $14.7M | $14.3M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $38.5M-5.8%1Y
- EBITDA
- $14.4M-12.3%1Y
- Net profit
- $11.3M-18.7%1Y
- Cash from operations
- $14.7M-0.9%1Y
- Free cash flow
- $14.3M-1.9%1Y
- Revenue CAGR, 3Y
- -9.7%
- Net profit CAGR, 3Y
- -11.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $38.5M | $14.4M | $11.3M | $14.3M | 9.5% | -5.8% | -18.7% |
Monthly returns
Month-by-month returns of UTMD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $122.5M |
| Current assets | $97.7M |
| Non-current assets | $24.8M |
| Liabilities | $3.3M |
| Current liabilities | $2.6M |
| Non-current liabilities | $680.0k |
| Equity | $119.3M |
| Paid-in capital | $0.00 |
| Retained earnings | $128.7M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; UTMD highlighted.
P/E against peers
UTMD trades at 19.2x earnings against a peer median of -2.7x.
Not shown (no positive earnings and no EV / Sales): Fulcrum Therapeutics, Inc., Inhibikase Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Utah Medical Products, Inc.UTMDthis company | $216.5M | 19.2x | 1.8x | 9.5% | 9.1x |
| Fulcrum Therapeutics, Inc.FULC | $224.6M | — | 0.6x | -21.5% | — |
| Foghorn Therapeutics Inc.FHTX | $219.6M | -3.0x | -2.0x | 68.5% | -2.3x |
| Inhibikase Therapeutics, Inc.IKT | $219.2M | -4.5x | 1.3x | -27.9% | -1.5x |
| Voyager Therapeutics, Inc.VYGR | $218.7M | -1.8x | 1.1x | -61.1% | -1.5x |
| Pro-Dex, Inc.PDEX | $213.9M | 23.8x | 5.8x | 24.5% | 16.3x |
| Keros Therapeutics, Inc.KROS | $213.2M | 2.4x | 0.7x | 28.7% | -0.8x |
| RxSight, Inc.RXST | $211.1M | -5.4x | 0.8x | -14.1% | -5.7x |
| Atrium Therapeutics, Inc.RNA | $210.4M | -2.7x | 1.0x | -37.0% | 0.7x |
| Peer median | — | -2.7x | 0.9x | -17.8% | -1.5x |
Year-to-date ROI
UTMD since 1 January, against earlier years.
Historical volatility
UTMD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 37.9% |
| FY2023 | 33.4% |
| FY2024 | 33.2% |
| FY2025 | 29.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $38.5M |
| Cost of revenueCost Of Revenue | $16.5M |
| Gross profitGross Profit | $22.0M |
| Operating expensesOperating Expense | $10.6M |
| Research and developmentResearch And Development | $670.0k |
| Selling, general and administrativeSelling General And Administration | $9.9M |
| Total expensesTotal Expenses | $27.1M |
| Operating incomeOperating Income | $11.4M |
| Interest and other | |
| Pretax incomePretax Income | $14.1M |
| TaxTax Provision | $2.8M |
| Net incomeNet Income | $11.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $122.5M |
| Current assetsCurrent Assets | $97.7M |
| Non-current assetsTotal Non Current Assets | $24.8M |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.3M |
| Current liabilitiesCurrent Liabilities | $2.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $680.0k |
| EquityTotal Equity Gross Minority Interest | $119.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $14.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $14.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $11.3M |
| Depreciation and amortisationDepreciation And Amortization | $3.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $3.0M |
| Depreciation | $880.0k |
| Amortization cash flowAmortization Cash Flow | $2.1M |
| Amortization of intangiblesAmortization Of Intangibles | $2.1M |
| Stock-based compensationStock Based Compensation | $370.0k |
| Deferred taxDeferred Tax | -$660.0k |
| Deferred income taxDeferred Income Tax | -$660.0k |
| Provision and write off of assetsProvisionand Write Offof Assets | $370.0k |
| Change in working capitalChange In Working Capital | $320.0k |
| Investing cash flowInvesting Cash Flow | -$370.0k |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$370.0k |
| Capital expenditureCapital Expenditure | -$370.0k |
| Capital expenditure (reported)Capital Expenditure Reported | -$370.0k |
| Purchase of PP&EPurchase Of PPE | — |
| Sale of PP&ESale Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | -$12.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$12.3M |
| Net common stock issuedNet Common Stock Issuance | -$8.4M |
| Common stock repurchasedCommon Stock Payments | -$8.4M |
| Share buybacksRepurchase Of Capital Stock | -$8.4M |
| Stock options exercisedProceeds From Stock Option Exercised | $0.00 |
| Dividends paidCash Dividends Paid | -$4.0M |
| Common dividends paidCommon Stock Dividend Paid | -$4.0M |
| Change in cashChanges In Cash | $2.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 80.0% |
| Cash at the start of the yearBeginning Cash Position | $83.0M |
| Cash at the end of the yearEnd Cash Position | $85.8M |
| Free cash flowFree Cash Flow | $14.3M |
| Supplemental |
Learn while you research
Academy chapters picked for Utah Medical Products, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read